Abstract：Objective To investigate the influence of reactive hyperemia index (RHI) on anthracycline-related cardiotoxicity and its predictive value. Methods The clinical data of 155 breast cancer patients who were treated with anthracycline chemotherapy in Jiangxi Cancer Hospital from April 2020 to September 2020 were retrospectively selected.All patients completed a 1-year follow-up after chemotherapy. According to the occurrence of cardiotoxicity within 1 year，they were divided into the cardiotoxicity group (n=10) and the non-cardiotoxicity group (n=145). After consulting and comparing the clinical data (baseline data and laboratory indicators) of the two groups, the independent risk factors of cardiotoxicity in anthracycline chemotherapy breast cancer patients were found by logistic regression analysis,and the predictive value of RHI on anthracycline-related cardiotoxicity was analyzed. Results The results of univariate analysis showed that RHI was a related factor affecting the cardiotoxicity of breast cancer patients undergoing anthracycline chemotherapy (P＜0.05). The results of multivariate analysis showed that low RHI was an independent risk factor of cardiotoxicity in breast cancer patients undergoing anthracycline chemotherapy (OR＞1, P＜0.05). The receiver operating characteristic curve (ROC) was drawn, and the results showed that the area under the curve (AUC) of RHI predicting the risk of anthracycline-related cardiotoxicity was 0.814, which was more predictive ideal. Conclusion RHI has certain predictive value for the risk of anthracycline-related cardiotoxicity in breast cancer patients.
京公网安备 11010502046607号